New combo therapy aims to outsmart drug-resistant lung cancer
NCT ID NCT07486648
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether adding capivasertib to osimertinib can help people with a specific type of advanced lung cancer whose disease has worsened after initial treatment. About 53 adults with EGFR-mutant NSCLC and additional PIK3CA/AKT1/PTEN gene changes will receive the two drugs together. The goal is to find a safe dose and see if the combination shrinks tumors or delays progression.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cancer Hospital Chinese Academy of Medical Sciences
Beijing, Beijing Municipality, China
Contact Email: •••••@•••••
-
Shanxi Cancer Hospital
Taiyuan, Shanxi, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a pill outperform chemo for a Hard-to-Treat lung cancer mutation?
- Can a smart drug home in on Hard-to-Treat cancers?
- Exercise as medicine: tailored workouts may rebuild strength after cancer
- Family support may be key to easing lung cancer surgery stress
- Can a Triple-Drug combo outsmart Immunotherapy-Resistant lung cancer?
- Can a drop of blood predict disease years before it strikes?